Literature DB >> 3334206

Total and local bone mineral during estrogen treatment: a placebo controlled trial.

A Gotfredsen1, B J Riis, C Christiansen.   

Abstract

103 healthy postmenopausal women with a natural menopause 0.5-2 years previously were randomized to either estrogen (n = 52) or placebo (n = 51) treatment. Total body bone mineral (TBBM) was measured by dual photon absorptiometry and forearm bone mineral content (BMC) by single photon absorptiometry before and after one year. Both TBBM and forearm BMC fell significantly (P less than 0.001) in the placebo group, but were unchanged after estrogen treatment. The loss of bone mineral in the placebo group during one year was 5% (TBBM) and 3% (forearm BMC). A significant correlation (r = 0.53; P less than 0.001) was found between the fractional percent change in forearm BMC and TBBM. It is concluded, that both the forearm BMC and the TBBM measurements are suitable for following changes in bone mass postmenopausally. The almost equal relative amount of cortical bone in the total skeleton and in the forearm BMC may explain that longitudinally performed forearm BMC measurements are indicative of average changes in the total skeletal status.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3334206

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  5 in total

Review 1.  Measurement of bone mineral density.

Authors:  C Hassager; C Christiansen
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

2.  Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist?

Authors:  C Hassager; S B Jensen; C Christiansen
Journal:  Osteoporos Int       Date:  1994-01       Impact factor: 4.507

3.  Rapid postmenopausal loss of total body and regional bone mass in normal southern Chinese females in Hong Kong.

Authors:  K K Pun; F H Wong; T Loh
Journal:  Osteoporos Int       Date:  1991-02       Impact factor: 4.507

4.  Demonstration of isoforms of the estrogen receptor in the bone tissues and in osteoblastic cells.

Authors:  S Hoshino; S Inoue; T Hosoi; T Saito; A Ikegami; M Kaneki; Y Ouchi; H Orimo
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

Review 5.  Epidemiology of osteoporosis. Implications for drug therapy.

Authors:  J Rungby; A Hermann; L Mosekilde
Journal:  Drugs Aging       Date:  1995-06       Impact factor: 3.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.